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gross national income (figure). In 
high-income countries, the price 
per bottle of sofosbuvir ranged 
from $14 000 (Spain) to $20 590 
(Switzerland). Prices for daclatasvir 
ranged from $1128 (South Korea) 
to $14 899 (Germany); those of 
simeprevir from $9166 (Spain) 
to $14 865 (Australia); those of 
ledipasvir-sofosbuvir from $12 604 
(USA) to $24 890 (Germany); 
and those of the 2D regimen 
from $15 344 (UK) to $20 215 
(Switzerland). 
In low-income and middle-income 
countries, prices were generally 
substantially lower than in high-
income countries. However, there 
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The introduction of direct-acting 
antiviral drugs (DAAs) is changing the 
treatment options for hepatitis C virus 
(HCV). These new medicines were 
initially marketed at a very high price, 
but several countries have negotiated 
favourable price reductions, and, in 
view of the low cost of production, 
further price reductions are anticipated, 
especially as the result of generic 
competition.1 Reliable, transparent, 
and updated information about drug 
availability and costs are important for 
policymakers, procurement agencies, 
providers, and people living with HCV 
to help ensure equitable access. 
We gathered price information 
in June, 2015, to inform decision 
making as part of the process of the 
WHO HCV Guidelines Development. 
A structured, piloted questionnaire 
was sent to key informants belonging 
to the WHO viral hepatitis experts 
network, including academics, 
policy makers, and civil society 
representatives of several countries, 
to collect information about 
availability and affordability of 
sofosbuvir, daclatasvir, ledipasvir-
sofosbuvir, simeprevir, ombitasvir-
paritaprevir-ritonavir, and dasabuvir. 
The following information was 
sought: availability in the public and 
private sector of originator drugs 
and generics, market price per bottle 
(US$), registration status, and special 
trading agreements (if applicable). To 
our knowledge, there are no stringent 
regulatory authority quality-assured 
generic sources of DAAs to date.
Information was available for 
38 countries, including 14 high-
income countries, nine upper middle-
income countries,  11 lower 
middle-income countries, and four low-
income countries. The questionnaire 
was sent to 92 key informants, and 
49 respondents agreed to provide 
information, and some people were 
able to provide information for several 
countries. 
The price per bottle of all 
originator DAAs varied substantially: 
for sofosbuvir it ranged from 
$300 (India, Pakistan) to $20 590 
(Switzerland); for daclatasvir from 
$175 (Egypt) to $14 899 (Germany); 
for simeprevir from $241 (Egypt) to 
$14 865 (Australia); for ledipasvir-
sofosbuvir from $400 (Egypt and 
Mongolia) to $24 890 (Germany); and 
for ombitasvir-paritaprevir-ritonavir 
(or 2D regimen) from $400 (Egypt) to 
$20 215 (Switzerland).
The greatest variability was noted 
in high-income countries, with little 
correlation between drug prices and 
Figure: Correlation between drug prices and gross national income 
(A) High-income countries. (B) Low-income and middle-income countries. Information on gross national 
income was obtained from the United Nations Development Programme.2
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majority of middle-income countries, 
where most of the HCV burden lies. 
For example, Argentina, Brazil, China, 
Georgia, Iran, Mexico, Peru, Turkey, 
and Ukraine are all excluded from 
Gilead’s voluntary license.3,4 
Furthermore, prices are still too 
high and unaﬀ ordable in settings in 
which people have to pay for their 
treatments or if high numbers of 
people require treatment in the public 
system. According to new therapeutic 
guidelines, treatment duration varies 
according to the stage of liver disease, 
with extended treatment durations 
from 3 to 6 months for patients with 
compensated cirrhosis.5 For example, 
in Egypt, 3 months’ treatment with 
sofosbuvir-daclatasvir costs $1350, 
but the cost will double if a person has 
cirrhosis and cannot take ribavirin. In 
Brazil, costs of sofosbuvir-daclatasvir 
treatment will  vary between 
$10 947 and $21 894 according 
to this same rule. In Germany, 
ledipasvir-sofosbuvir costs between 
$75 000 and $150 000 and 6 months’ 
treatment with sofosbuvir-daclatasvir 
costs $150 366 in France.
Manufacturing costs of DAAs are 
estimated to be far lower than the 
current prices. Generic competition 
from multiple manufacturers is already 
indicating a downward trend for the 
prices of sofosbuvir, which should 
enable low-cost access to quality-
assured generic versions of this drug. 
Several manufacturers are also starting 
generic production of sofosbuvir-
daclatasvir and ledipasvir-sofosbuvir.
Even if countries are excluded 
from voluntary licenses or face 
patent barriers, these obstacles do 
not necessarily preclude them from 
pursuing access to low-cost generics if 
adequate legal measures and strategies 
can be put in place. However, to 
achieve this access, understanding the 
patent landscape of key DAAs is a pre-
requisite, a strict patent examination 
would prevent granting of weak or 
invalid DAA patents, and the use 
of compulsory licenses should be 
considered where necessary.
were some clear outliers (figure). 
Côte d’Ivoire is paying almost three 
times as much for sofosbuvir as is 
India ($500 per bottle for the generic 
drug in Côte d’Ivoire vs $300 for the 
originator in India, where the generic 
drug costs $312–161) despite having 
a far lower gross national income 
($2774 for Côte d’Ivoire vs $5150 for 
India). South Africa is paying six times 
more for simeprevir than is Brazil 
($6100 vs $1000) despite having a 
lower gross national income ($11 788 
for South Africa vs $14 275 for Brazil). 
In Malaysia the cost of sofosbuvir 
($18 000) and ledipasvir-sofosbuvir 
($22 000) is higher than in many high-
income countries; similarly, ledipasvir-
sofosbuvir ($21 988) costs more in 
Turkey than in many high-income 
countries. In Egypt, a local generic of 
sofosbuvir is also available at $343, 
which is expected to decrease to about 
$100. Several sources of generics of 
sofosbuvir are available in India with 
prices ranging from $161 to $312. 
With the exception of sofosbuvir, 
most DAAs were very poorly available 
in low-income countries.
This survey highlights the high 
diversity in market prices in low-
income, middle-income, and high-
income countries. Having access to 
updated reliable price information 
can allow country decision makers 
to negotiate better prices. High-
burden countries such as Egypt, 
Mongolia, India, Pakistan, and 
Brazil set the scene for increased 
competition between pharmaceutical 
companies, including through generic 
competition.
Gilead has signed voluntary 
licensing agreements with 11 Indian 
manufacturers of generic medicines 
to market generic versions of 
Gilead’s DAAs (such as sofosbuvir 
and ledipasvir-sofosbuvir) in some 
low-income and middle-income 
countries, and Bristol-Myers Squibb 
is also investigating voluntary 
license agreements with generic 
manufacturers. However, these 
voluntary licenses do not apply to the 
